You are here

Industry Trends

FDA and some companies dispute findings of report in NEJM
Those in development are at best short-term solutions
Company aims to prevent Restasis challenges at U.S. patent office
Studies at ESMO may lead to wider use of medications
Quest Analysis of 3.4 million tests shows evidence of dangerous drug combinations
In 13 years, use of paper-only patient health records fell from 69% to 1%
More timely stroke care can improve patient outcomes
The drop occurred with both brick-and-mortar and mail-order pharmacies
Company faces the challenge of proving the complex treatment can be manufactured and administered at commercial scale
Some analysts find the price “cost-effective,” while advocates decry it as “excessive”
New economic analysis suggests the drug is worth the $9,669 annual price tag
Annual list costs need to drop dramatically to meet cost-effectiveness thresholds
New medical device user fee agreement establishes central digital health unit